GCP
ACOR

GSA Capital Partners’s Acorda Therapeutics ACOR Stock Holding History

GSA Capital Partners’s Portfolio ACOR Stock Details ACOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-5,601
Closed -$346K – 1707
2020
Q3 		$346K Buy
5,601
+5,151
+1,145% +$388K 0.06% 641
2020
Q2 		$40K Sell
450
-1,636
-78% -$173K 0.02% 544
2020
Q1 		$233K Buy
+2,086
New +$411K 0.06% 656
2019
Q4 		– Sell
-152
Closed -$52K – 1819
2019
Q3 		$52K Buy
+152
New +$82.6K 0.01% 1321
2019
Q2 		– Sell
-545
Closed -$869K – 1820
2019
Q1 		$869K Buy
545
+37
+7% +$66.7K 0.09% 367
2018
Q4 		$949K Hold
508
– – 0.11% 240
2018
Q3 		$1.2M Buy
+508
New +$1.57M 0.07% 559
2018
Q2 		– Sell
-699
Closed -$1.98M – 2001
2018
Q1 		$1.98M Buy
+699
New +$2.09M 0.11% 294
2017
Q4 		– Sell
-191
Closed -$541K – 1890
2017
Q3 		$541K Buy
+191
New +$503K 0.04% 918
2016
Q4 		– Sell
-185
Closed -$463K – 2019
2016
Q3 		$463K Buy
185
+11
+6% +$32.8K 0.02% 1105
2016
Q2 		$532K Sell
174
-242
-58% -$787K 0.03% 1032
2016
Q1 		$1.32M Buy
416
+247
+146% +$1.03M 0.08% 397
2015
Q4 		$867K Sell
169
-343
-67% -$1.5M 0.04% 802
2015
Q3 		$1.63M Buy
512
+363
+244% +$1.41M 0.08% 364
2015
Q2 		$596K Sell
149
-140
-48% -$541K 0.02% 1238
2015
Q1 		$1.16M Sell
289
-66
-19% -$302K 0.05% 744
2014
Q4 		$1.74M Buy
355
+73
+26% +$313K 0.12% 186
2014
Q3 		$1.15M Sell
282
-21
-7% -$78.8K 0.06% 409
2014
Q2 		$1.22M Buy
303
+177
+140% +$722K 0.06% 539
2014
Q1 		$571K Sell
126
-134
-52% -$542K 0.04% 694
2013
Q4 		$912K Buy
260
+132
+103% +$515K 0.07% 426
2013
Q3 		$527K Buy
128
+16
+14% +$68.9K 0.04% 752
2013
Q2 		$444K Buy
+112
New +$461K 0.05% 619

Other funds holding ACOR

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

GSA Capital Partners's ACOR Position: Q4 2020 in Review

GSA Capital Partners sold out of Acorda Therapeutics (ACOR) in Q4 2020, closing a stake of 5,601 shares — an estimated $346K sold.

GSA Capital Partners first reported a position in ACOR in Q2 2013 and held it in 23 quarters. The position peaked at $1.98M in Q1 2018. 47 funds tracked by Wall St. Rank hold ACOR as of Q4 2020.

  • GSA Capital Partners reported no remaining Acorda Therapeutics position as of Q4 2020 after selling out during the quarter.
  • GSA Capital Partners sold 5,601 Acorda Therapeutics shares in Q4 2020, an estimated $346K.
  • GSA Capital Partners first reported a position in Acorda Therapeutics in Q2 2013 and held it in 23 quarters.
  • GSA Capital Partners's Acorda Therapeutics position peaked at $1.98M in Q1 2018.
  • 47 funds tracked by Wall St. Rank held Acorda Therapeutics as of Q4 2020.

Based on GSA Capital Partners's 13F filing for Q4 2020, filed 3 Feb 2021.